{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:24:04Z","timestamp":1790753044470,"version":"4.1.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,1,2]],"date-time":"2019-01-02T00:00:00Z","timestamp":1546387200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"BC"},{"name":"F. Hoffmann\u2013La Roche, Ltd."}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.ejca.2018.12.022","type":"journal-article","created":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T04:28:14Z","timestamp":1548822494000},"page":"92-102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":97,"special_numbering":"C","title":["Safety of trastuzumab emtansine (T-DM1)\u00a0in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1"],"prefix":"10.1016","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4231-2291","authenticated-orcid":false,"given":"Filippo","family":"Montemurro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Anton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Wuerstlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzette","family":"Delaloge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Bonneterre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Quenel-Tueux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine C.","family":"Linn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsumi","family":"Irahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Donica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Lindegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos H.","family":"Barrios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2018.12.022_bib1","series-title":"KADCYLA\u00ae (ado-trastuzumab emtansine) for injection [package insert]","year":"2016"},{"key":"10.1016\/j.ejca.2018.12.022_bib2","series-title":"KADCYLA\u00ae (ado-trastuzumab emtansine) [Summary of product characteristics]","year":"2017"},{"key":"10.1016\/j.ejca.2018.12.022_bib3","series-title":"NCCN clinical practice guidelines in oncology: breast cancer version 2","author":"National Comprehensive Cancer Network","year":"2017"},{"issue":"19","key":"10.1016\/j.ejca.2018.12.022_bib4","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ejca.2018.12.022_bib5","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1470-2045(14)70178-0","article-title":"Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomized, open-label, phase 3 trial","volume":"15","author":"Krop","year":"2014","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2018.12.022_bib6","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S1470-2045(17)30313-3","article-title":"Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial","volume":"18","author":"Krop","year":"2017","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2018.12.022_bib7","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1200\/JCO.2016.67.4887","article-title":"Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: primary results from the phase III MARIANNE study","volume":"35","author":"Perez","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2018.12.022_bib8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.ejca.2018.12.022_bib9","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1200\/JCO.2013.54.4999","article-title":"Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis","volume":"32","author":"Di\u00e9ras","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.12.022_bib10","series-title":"Presented at San Antonio Breast Cancer Symposium, December 6\u201310","article-title":"Safety and efficacy of trastuzumab emtansine (T-DM1) in 399 patients with central nervous system metastases: exploratory subgroup analysis from the KAMILLA study","author":"Montemurro","year":"2016"},{"key":"10.1016\/j.ejca.2018.12.022_bib11","doi-asserted-by":"crossref","first-page":"i5078","DOI":"10.1136\/bmj.i5078","article-title":"Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry\/journal editor perspective","volume":"355","author":"Lineberry","year":"2016","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.ejca.2018.12.022_bib12","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/annonc\/mdv485","article-title":"The reporting of adverse events in oncology phase III trials: a comparison of the current status versus the expectations of the EORTC members","volume":"27","author":"Maillet","year":"2016","journal-title":"Ann Oncol"},{"issue":"31","key":"10.1016\/j.ejca.2018.12.022_bib13","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1200\/JCO.2013.49.3981","article-title":"Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: a systematic review","volume":"31","author":"P\u00e9ron","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2018.12.022_bib14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1200\/JCO.2013.52.2219","article-title":"Adverse event reporting in cancer clinical trial publications","volume":"32","author":"Sivendran","year":"2014","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2018.12.022_bib15","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1080\/14740338.2016.1175429","article-title":"Adverse event reporting in oncology clinical trials \u2013 lost in translation?","volume":"15","author":"Sivendran","year":"2016","journal-title":"Expert Opin Drug Saf"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918315776?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918315776?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:23:40Z","timestamp":1760732620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804918315776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":15,"alternative-id":["S0959804918315776"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.12.022","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of trastuzumab emtansine (T-DM1)\u00a0in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.12.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}